MedTrace Logo

Pre-exposure Prophylaxis for SARS-Coronavirus-2

NCT04328467 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1483

Last updated 2021-07-02

Study results available
· View outcomes & findings →

Summary

Objective: To determine if pre-exposure prophylaxis with hydroxychloroquine is effective for the prevention of COVID-19 disease.

Conditions

  • COVID-19
  • Corona Virus Infection
  • ARDS
  • Acute Respiratory Distress Syndrome

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine; 200mg tablet; oral

OTHER

Placebo

Placebo; tablet; oral

Sponsors & Collaborators

Principal Investigators

  • Radha Rajasingham, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-06
Primary Completion
2020-07-13
Completion
2020-07-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328467 on ClinicalTrials.gov